Literature DB >> 12427898

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.

M Rovaris1, M Codella, L Moiola, A Ghezzi, M Zaffaroni, G Mancardi, E Capello, F Sardanelli, G Comi, M Filippi.   

Abstract

This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12427898     DOI： 10.1212/01.wnl.0000033800.93899.e1

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

2.  Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.

Authors:  J O Fleming; A Isaak; J E Lee; C C Luzzio; M D Carrithers; T D Cook; A S Field; J Boland; Z Fabry
Journal:  Mult Scler       Date:  2011-03-03       Impact factor: 6.312

Review 3.  The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome.

Authors:  Robert Zivadinov; Milena Stosic; Jennifer L Cox; Deepa P Ramasamy; Michael G Dwyer
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

4.  The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis.

Authors:  F Sardanelli; S Schiavoni; A Iozzelli; A Fausto; A Aliprandi; G L Mancardi; M Filippi
Journal:  Radiol Med       Date:  2007-12-13       Impact factor: 3.469

5.  Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.

Authors:  Robert Zivadinov; David Hojnacki; Sara Hussein; Niels Bergsland; Ellen Carl; Jacqueline Durfee; Michael G Dwyer; Cheryl Kennedy; Bianca Weinstock-Guttman
Journal:  Int J Mol Sci       Date:  2012-05-10       Impact factor: 6.208

6.  Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.

Authors:  Mat D Davis; Natalia Ashtamker; Joshua R Steinerman; Volker Knappertz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.